Novel index based on inflammatory markers correlates with treatment efficacy of nivolumab for recurrent/metastatic head and neck cancer.

IF 2.5 3区医学 Q3 ONCOLOGY Oncology Pub Date : 2024-11-20 DOI:10.1159/000542683

Hiroe Tada, Reika Kawabata-Iwakawa, Hideyuki Takahashi, Kazuaki Chikamatsu

{"title":"Novel index based on inflammatory markers correlates with treatment efficacy of nivolumab for recurrent/metastatic head and neck cancer.","authors":"Hiroe Tada, Reika Kawabata-Iwakawa, Hideyuki Takahashi, Kazuaki Chikamatsu","doi":"10.1159/000542683","DOIUrl":null,"url":null,"abstract":"Introduction: Immune checkpoint inhibitors provide new treatments for patients with recurrent or metastatic (R/M) head and neck cancers. Herein, we focused on systemic inflammatory markers in peripheral blood, including blood cell fractions, albumin, and C-reactive protein, and determined their association with nivolumab treatment response. We also examined the potential application of inflammatory markers as prognostic tools.Methods: We assessed pre-treatment systemic inflammatory markers in 61 patients with R/M head and neck cancer treated with nivolumab, determining their association with treatment response using Kaplan-Meier, multivariate, and regression analyses. Using flow cytometry, we investigated circulating T cell subsets in 36 patients with R/M head and neck cancer. Finally, we examined the correlation between each statistically analyzed parameter and peripheral circulating T cell activation.Results: Systemic inflammatory marker values were used to estimate overall survival time by performing multivariate analysis. Systemic inflammatory markers were assigned importance for each coefficient. Monocyte and lymphocyte counts strongly impacted overall survival. Indices dependent on white blood cell and monocyte counts, lymphocyte percentage, platelet count, albumin levels, and prognostic nutrition index were useful prognostic tools in the regression analysis. The simplest prognostic index was defined as white blood cells (103/μL) +2×lymphocyte percentage (%) +12×number of monocytes (103/μL)+27×serum albumin. A high index that was significantly associated with a better prognosis negatively correlated with CD38/CD8 and ki67/CD8 percentages.Conclusions: According to the findings of the present study, systemic inflammatory markers may help predict the prognosis, activation, and exhaustion of circulating T cells. In patients with R/M head and neck cancer treated with nivolumab, systemic inflammatory markers could provide new insights into rational strategies in cancer immunotherapy for R/M head and neck cancer.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-22"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542683","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Immune checkpoint inhibitors provide new treatments for patients with recurrent or metastatic (R/M) head and neck cancers. Herein, we focused on systemic inflammatory markers in peripheral blood, including blood cell fractions, albumin, and C-reactive protein, and determined their association with nivolumab treatment response. We also examined the potential application of inflammatory markers as prognostic tools.

Methods: We assessed pre-treatment systemic inflammatory markers in 61 patients with R/M head and neck cancer treated with nivolumab, determining their association with treatment response using Kaplan-Meier, multivariate, and regression analyses. Using flow cytometry, we investigated circulating T cell subsets in 36 patients with R/M head and neck cancer. Finally, we examined the correlation between each statistically analyzed parameter and peripheral circulating T cell activation.

Results: Systemic inflammatory marker values were used to estimate overall survival time by performing multivariate analysis. Systemic inflammatory markers were assigned importance for each coefficient. Monocyte and lymphocyte counts strongly impacted overall survival. Indices dependent on white blood cell and monocyte counts, lymphocyte percentage, platelet count, albumin levels, and prognostic nutrition index were useful prognostic tools in the regression analysis. The simplest prognostic index was defined as white blood cells (103/μL) +2×lymphocyte percentage (%) +12×number of monocytes (103/μL)+27×serum albumin. A high index that was significantly associated with a better prognosis negatively correlated with CD38/CD8 and ki67/CD8 percentages.

Conclusions: According to the findings of the present study, systemic inflammatory markers may help predict the prognosis, activation, and exhaustion of circulating T cells. In patients with R/M head and neck cancer treated with nivolumab, systemic inflammatory markers could provide new insights into rational strategies in cancer immunotherapy for R/M head and neck cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

基于炎症标志物的新指数与尼伐单抗治疗复发/转移性头颈癌的疗效相关。

简介：免疫检查点抑制剂为复发性或转移性（R/M）头颈部癌症患者提供了新的治疗方法。在此，我们重点研究了外周血中的全身性炎症标志物，包括血细胞组分、白蛋白和 C 反应蛋白，并确定了它们与 nivolumab 治疗反应的关系。我们还研究了炎症标志物作为预后工具的潜在应用：我们评估了61名接受尼妥珠单抗治疗的R/M头颈癌患者的治疗前全身炎症指标，并使用卡普兰-梅耶、多变量和回归分析确定了这些指标与治疗反应的关系。我们使用流式细胞术研究了 36 名 R/M 头颈癌患者的循环 T 细胞亚群。最后，我们研究了每个统计分析参数与外周循环 T 细胞活化之间的相关性：结果：通过多变量分析，全身炎症标志物值被用于估算总生存时间。全身炎症标志物被赋予了各项系数的重要性。单核细胞和淋巴细胞计数对总生存期有很大影响。在回归分析中，取决于白细胞和单核细胞计数、淋巴细胞百分比、血小板计数、白蛋白水平和预后营养指数的指数是有用的预后工具。最简单的预后指数定义为白细胞（103/μL）+2×淋巴细胞百分比（%）+12×单核细胞数（103/μL）+27×血清白蛋白。高指数与较好的预后明显相关，与 CD38/CD8 和 ki67/CD8 百分比呈负相关：根据本研究的结果，全身炎症标志物有助于预测预后、循环 T 细胞的活化和衰竭。在接受尼妥珠单抗治疗的R/M头颈癌患者中，全身炎症标志物可为R/M头颈癌癌症免疫疗法的合理策略提供新的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.